| Aug 11 |
Amneal Pharmaceuticals Second Quarter 2024 Earnings: EPS: US$0.019 (vs US$0.078 in 2Q 2023)
|
| Aug 9 |
Amneal Pharmaceuticals, Inc. (AMRX) Q2 2024 Earnings Call Transcript
|
| Aug 9 |
Amneal Pharmaceuticals beats top-line and bottom-line estimates; raises FY24 outlook
|
| Aug 9 |
Amneal Reports Second Quarter 2024 Financial Results
|
| Aug 8 |
Amneal Pharmaceuticals Q2 2024 Earnings Preview
|
| Aug 7 |
Amneal gets FDA approval for Crexont for Parkinson's disease
|
| Aug 7 |
Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules
|
| Jul 29 |
Amneal gets FDA approval for potassium phosphate IV bags
|
| Jul 29 |
Amneal Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags
|
| Jul 27 |
In spite of recent selling, insiders still control 53% of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)
|
